The Therapeutic Potentials of Ayahuasca in the Treatment of Depression
The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic “ayahuasca” for neuropsychiatric disorders such as depression and anxiety.”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [2]
In the citing paper
“Indeed, converging evidence from preclinical and human studies suggest that oral formulations of DMT such as ayahuasca show potential in reducing anxiety, depressive symptoms, addictive behaviors, and posttraumatic distress (1–3, 30–35).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [2]
Citations
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761 · cited 1×
“involving self-judgments, recall of autobiographical memories, mental simulations, mind-wandering, and daydreaming (Buckner et al. 2008; Northoff et al. 2006).”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“the brain (Zarate 2011; Zarate et al. 2006).”
BackgroundSelf-referential processing in our brain—A meta-analysis of imaging studies on the self
Northoff, G., Heinzel, A., de Greck, M., Bermpohl, F., Dobrowolny, H., & Panksepp, J. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.12.002 · Cited by 2,792
Greicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., Reiss, A. L., & Schatzberg, A. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.020 · Cited by 2,214 · cited 1×
“, increased DMN activity and functional connectivity (Greicius et al. 2007; Sheline et al. 2009).”
BackgroundHippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670 · cited 2×
“The neurodegenerative hypothesis is based on the fact that many depressed patients have reduced hippocampal volume (Bremner et al. 2000).”
BackgroundResultCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654 · cited 2×
“Moreover, there are antidepressants with multiple action mechanisms, such as mirtazapine, which acts as a noradrenergic pre-synaptic a2receptor antagonist and serotonin (5HT2 and 5HT3) antagonist, and nefazodone which act by inhibiting the reuptake of serotonin and norepinephrine, and as a 5HT and a2 antagonist (Cipri…”
BackgroundThe default mode network and self-referential processes in depression
Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., Mintun, M. A., Wang, S., Coalson, R. S., & Raichle, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812686106 · Cited by 1,480 · cited 1×
“, increased DMN activity and functional connectivity (Greicius et al. 2007; Sheline et al. 2009).”
BackgroundSleep and Psychiatric Disorders: A Meta-analysis
Benca, R. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080059010 · Cited by 1,468 · cited 3×
“Furthermore, the connection between REM sleep and depression has been demonstrated by the fact that acute sleep deprivation (total, partial, or specifically REM sleep) alleviates depressive symptoms (Benca et al. 1992; Riemann et al. 2001).”
BackgroundSheline, Y. I., Price, J. L., Yan, Z., & Mintun, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000446107 · Cited by 1,196 · cited 1×
“Abnormalities in functional connectivity of other networks were also found in depressive patients (Anand et al. 2005; Sheline et al. 2010; Veer et al. 2010).”
BackgroundSheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01263-x · Cited by 1,191 · cited 1×
“Studies using functional magnetic resonance imaging (fMRI) showed hyperactivity of the amygdala of depressed patients (Davey et al. 2011; Sheline et al. 2001).”
BackgroundShimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 1×
“Instead, it can be a result of a reduction in neurogenesis induced by high glucocorticoid, pro-inflammatory cytokine levels and reduced serotonin availability, which in turn can inhibit the production of cell growth factors such as brain derived neurotropic factor (BDNF) (Shimizu et al. 2003).”
BackgroundJournal of Psychiatry and Neuroscience
(2025) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn · Cited by 1,128
Tsuno, N., Besset, A., & Ritchie, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1008 · Cited by 1,084 · cited 2×
“(interval between sleep onset and the occurrence of the first REM period), increased amount of REM sleep, longer first REM period, increased REM density (number of eye movements during REM), and reduced slow-wave sleep (Benca et al. 1992; Riemann et al. 2001; Tsuno et al. 2005).”
BackgroundWhole brain resting-state analysis reveals decreased functional connectivity in major depression
Veer, I. M. (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00041 · Cited by 753
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727 · cited 1×
“Despite substantial progress in the development of new drugs, less than 50 % of patients achieve remission as a result of antidepressant use, even after four different pharmacological treatment regimes (Warden et al. 2007).”
BackgroundResearch and treatment approaches to depression
Wong, M.-L., & Licinio, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072566 · Cited by 656 · cited 1×
“nephrine, and serotonin (Wong and Licinio 2001).”
Sleep and depression--results from psychobiological studies: an overview
Riemann, D., Berger, M., & Voderholzer, U. (2001) · Biological Psychology · doi:10.1016/s0301-0511(01)00090-4 · Cited by 653 · cited 4×
“Furthermore, the connection between REM sleep and depression has been demonstrated by the fact that acute sleep deprivation (total, partial, or specifically REM sleep) alleviates depressive symptoms (Benca et al. 1992; Riemann et al. 2001).”
BackgroundInfluentialPace, T. W. W., Hu, F., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.08.009 · Cited by 621 · cited 1×
“In turn, the massive liberation of pro-inflammatory cytokines induces a decrease in GR function (Pace et al. 2007).”
BackgroundAbnormal gray and white matter volume in delusional infestation
Wolf, R. C., Huber, M., Depping, M. S., Thomann, P. A., Karner, M., Lepping, P., & Freudenmann, R. W. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.004 · Cited by 606
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Textbook of psychopharmacology
Edwards, G. (1975) · Nature · doi:10.1038/258648b0 · Cited by 585
Glucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554 · cited 1×
“patients have impaired glucocorticoid receptor (GR) function, which results in reduced negative feedback in the HPA system, leading to chronically high levels of adrenocorticotrophic hormone-releasing factor (CRF), and increased cortisol in the plasma, urine, and cerebrospinal fluid (Zunszain et al. 2011).”
BackgroundLorenzetti, V., Allen, N. B., Fornito, A., & Yücel, M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.021 · Cited by 553 · cited 2×
“One of the most consistent results is the reduction of hippocampal volume in MDD (Bremner et al. 2000; Lorenzetti et al. 2009; MacQueen 2009).”
BackgroundResultInterpersonal Psychotherapy for Depression: A Meta-Analysis
Cuijpers, P., Geraedts, A. S., van Oppen, P., Andersson, G., Markowitz, J. C., & van Straten, A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10101411 · Cited by 511 · cited 1×
“2010), psychotherapy (Cuijpers et al. 2011), electroconvulsive therapy (Andrade et al.”
BackgroundRecent developments and current controversies in depression
Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67964-6 · Cited by 434 · cited 2×
“MDD is associated with intense personal suffering, high morbidity, and increased mortality (Ebmeier et al. 2006).”
BackgroundMethodSegal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429 · cited 1×
“somatic therapies (Segal et al. 2010).”
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390 · cited 3×
“These effects begin between 35 and 40 min after tea ingestion, reaching their height between 90 and 120 min, and lasting for 4 h (Riba et al. 2003).”
BackgroundInflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342
Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338 · cited 1×
“Thus far, all studies to date have demonstrated the safety of ayahuasca, with reports of individuals who have used it for more than 30 years without evidence of harm to health (Callaway et al. 1999; Grob et al. 1996; Riba et al. 2001; Riba et al. 2003).”
BackgroundAntidepressant Effect on Connectivity of the Mood-Regulating Circuit: An fMRI Study
Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., Mathews, V. P., Kalnin, A., & Lowe, M. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300725 · Cited by 324 · cited 1×
“Abnormalities in functional connectivity of other networks were also found in depressive patients (Anand et al. 2005; Sheline et al. 2010; Veer et al. 2010).”
BackgroundMcKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321 · cited 1×
“Their main action in ayahuasca is apparently to protect DMT from peripheral degradation, preventing oxidative deamination of the orally ingested DMT and enabling it to reach the central nervous system (McKenna 2004).”
BackgroundKnorr, U., Vinberg, M., Kessing, L. V., & Wetterslev, J. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.04.001 · Cited by 317 · cited 1×
“However, this is generally not considered a reliable strategy for use with depressed patients (Knorr et al. 2010).”
BackgroundPharmacokinetics of Hoasca alkaloids in healthy humans
Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., Andrade, E. N., Andrade, E. O., & Mash, D. C. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(98)00168-8 · Cited by 315 · cited 1×
“Thus far, all studies to date have demonstrated the safety of ayahuasca, with reports of individuals who have used it for more than 30 years without evidence of harm to health (Callaway et al. 1999; Grob et al. 1996; Riba et al. 2001; Riba et al. 2003).”
BackgroundRiba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303 · cited 2×
“The effects of ayahuasca are heterogeneous (Riba et al. 2001), and encompass sensory, cognitive, and affective changes (Prado et al.”
BackgroundMiura, H., Ozaki, N., Sawada, M., Isobe, K., Ohta, T., & Nagatsu, T. (2008) · Stress · doi:10.1080/10253890701754068 · Cited by 282 · cited 1×
“Taken together, a link between these three theories has been observed: The excess of circulating corticosteroids and pro-inflammatory cytokines increases activity of indoleamine 2,3-dioxygenase (IDO), an enzyme which induces formation of kynurenine in the tryptophan-kynurenine pathway, resulting in the deficiency of s…”
BackgroundClinical guidelines for the treatment of depressive disorders.
(2001) · PubMed · Cited by 274
Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Self-citationAssessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227 · cited 1×
“Furthermore, a recent study showed that the ritual use of the tea is not associated with the psychosocial problems that are usually found with other drugs (Fábregas et al. 2010).”
BackgroundBerry, A., Bellisario, V., Capoccia, S., Tirassa, P., Calza, A., Alleva, E., & Cirulli, F. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.09.007 · Cited by 223
Wegener, G. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01719.x · Cited by 214
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.04.012 · Cited by 205 · cited 1×
“double blind, placebo controlled experiment indicated that the use of ayahuasca significantly reduces the scores of behavioral scales of panic and hopelessness in participants who were under the influence of the tea compared to a control group (Santos et al. 2007).”
BackgroundDo antidepressants regulate how cortisol affects the brain?
Pariante, C. M., Thomas, S. A., Lovestone, S., Makoff, A., & Kerwin, R. W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2003.10.009 · Cited by 194
Increased Waking Salivary Cortisol Levels in Young People at Familial Risk of Depression
Mannie, Z. N., Harmer, C. J., & Cowen, P. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.4.617 · Cited by 192 · cited 1×
“1995) and dysregulation of the HPA axis (Mannie et al. 2007) in otherwise healthy adults, but whose first-degree relatives had a history of depressive disorder.”
BackgroundKennedy, S. H., Lam, R. W. M., Cohen, N. L., & Ravindran, A. V. (2001) · PubMed · Cited by 191
MUÑOZ, R. A. (2002) · American Journal of Psychiatry · doi:10.1176/ajp.159.6.1066 · Cited by 189
Is impaired neurogenesis relevant to the affective symptoms of depression?
Sapolsky, R. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.012 · Cited by 188 · cited 1×
“Studies suggest that such reduction does not come only as a consequence of neuronal death (Sapolsky 2004).”
BackgroundNeuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167 · cited 2×
“In line with this evidence, rapid increase in cortisol levels was observed in a single acute treatment with antidepressants like reboxetine that act on the serotoninergic system (Schüle 2006).”
BackgroundAnxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety
Nic Dhonnchadha, B. Á., Bourin, M., & Hascoët, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00311-x · Cited by 165 · cited 1×
“Furthermore, the use of (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a powerful 5HT2A/2C agonist, resulted in positive responses in two models of anxiety in mice (Dhonnchadha et al. 2003).”
MethodCozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., & Ruoho, A. E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0308-8 · Cited by 162 · cited 2×
“Hence, the DMT can be released into the synaptic cleft upon vesicular fusion to interact with cell-surface sigma-1 receptors or serotonin postsynaptic receptors (Cozzi et al. 2009).”
BackgroundIn Quest of Identifying Vulnerability Markers for Psychiatric Disorders by All-Night Polysomnography
Lauer, C. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140063009 · Cited by 146 · cited 1×
“Other investigators reported sleep disorders (Lauer et al. 1995) and dysregulation of the HPA axis (Mannie et al.”
BackgroundPharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Biomarkers to Predict Antidepressant Response
Leuchter, A. F., Cook, I. A., Hamilton, S. P., Narr, K. L., Toga, A., Hunter, A. M., Faull, K., Whitelegge, J., Andrews, A. M., Loo, J., et al. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0160-4 · Cited by 140 · cited 3×
“The use of biomarkers has an important role in understanding and monitoring conventional and alternative treatments (Leuchter et al. 2010).”
BackgroundEndogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine
Jacob, M., & Presti, D. E. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.11.005 · Cited by 138 · cited 1×
“Some hypotheses have emerged that, at low doses, the anxiolytic mechanism associated with DMT would be mediated by a trace amine receptor, which could be one of the sites of action of endogenous DMT (Jacob and Presti 2005).”
Backgrounddos Santos, R. G., Valle, M., Bouso, J. C., Nomdedéu, J. F., Rodríguez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 136
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F. P., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.008 · Cited by 117 · cited 1×
“It has recently been found that the use of harmine alone in rodent models leads to the reduction of various signs and symptoms associated with depression, such as anhedonia, and regulation to normal levels of ACTH and hippocampal BDNF (Fortunato et al. 2010).”
BackgroundSelf-citationWhen the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor
Su, T.-P., Hayashi, T., & Vaupel, D. B. (2009) · Science Signaling · doi:10.1126/scisignal.261pe12 · Cited by 110 · cited 1×
“Therefore, high intracellular and vesicular concentrations of DMT may be achieved inside of neurons, and can interact with intracellular sigma1 receptors located in the mitochondria-associated endoplasmic reticulum membrane (Su et al. 2009).”
BackgroundBiomarkers in psychiatry: drawbacks and potential for misuse
Lakhan, S. E., Vieira, K., & Hamlat, E. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-1 · Cited by 107 · cited 1×
“(Lakhan et al. 2010).”
Davey, C. G., Allen, N. B., Harrison, B. J., & Yücel, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.004 · Cited by 98 · cited 1×
“Studies using functional magnetic resonance imaging (fMRI) showed hyperactivity of the amygdala of depressed patients (Davey et al. 2011; Sheline et al. 2001).”
BackgroundPolysomnographic parameters in first-degree relatives of unipolar probands
Giles, D. E., Kupfer, D. J., Roffwarg, H. P., Rush, A. J., Biggs, M. M., & Etzel, B. A. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90128-5 · Cited by 88 · cited 1×
“They also found shortened REM latency, even in psychiatrically asymptomatic first-degree relatives of depressed probands (Giles et al. 1989).”
BackgroundDaytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers
Barbanoj, M. J., Riba, J., Clos, S., Giménez, S., Grasa, E., & Romero, S. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0963-0 · Cited by 86 · cited 1×
“A trend increase in REM latency was also reported (Barbanoj et al. 2008).”
BackgroundMagnetic resonance imaging and prediction of outcome in patients with major depressive disorder
MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0945 · Cited by 84 · cited 1×
“One of the most consistent results is the reduction of hippocampal volume in MDD (Bremner et al. 2000; Lorenzetti et al. 2009; MacQueen 2009).”
ResultHarmane Induces Anxiolysis and Antidepressant‐Like Effects in Rats
ARICIOGLU, F., & ALTUNBAS, H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1304.024 · Cited by 83
Risk factors in families of unipolar depression. I. Psychiatric illness and reduced REM latency
Giles, D. E., Biggs, M. M., Rush, A. J., & Roffwarg, H. P. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90071-7 · Cited by 82 · cited 1×
“They reported that the relative risk for MDD in relatives with reduced REM latency was almost three times greater than for relatives with non-reduced REM latency (Giles et al. 1988).”
BackgroundSchüle, C., Baghai, T. C., Eser, D., Zwanzger, P., Jordan, M., Buechs, R., & Rupprecht, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0382-7 · Cited by 77 · cited 1×
“5 weeks of treatment with reboxetine in depressed patients (Schüle et al. 2006).”
BackgroundIntravenous ketamine therapy in a patient with a treatment-resistant major depression
Liebrenz, M., Borgeat, A., & Leisinger, R. (2007) · Swiss Medical Weekly · doi:10.4414/smw.2007.11852 · Cited by 75 · cited 1×
“For instance, studies conducted with ketamine, an NMDA antagonist, showed antidepressant effects after a single intravenous injection, which persisted significantly after 1 week (Liebrenz et al. 2007).”
BackgroundZhou, J., Li, L., Tang, S., Cao, X., Li, Z., Li, W., Li, C.-Q., & Zhang, X. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.009 · Cited by 67 · cited 1×
“2012) have shown that social deprivation in mice leads to increased depressive-like behaviors, elevated corticosterone levels, and reduced BDNF levels (Zhou et al. 2008).”
BackgroundMcKenna, D. J., Towers, G. H. N., & Abbott, F. S. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90048-5 · Cited by 63
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53 · cited 2×
“Moreover, plasmatic pro-inflammatory cytokine levels, which are reported to be increased in MDD, are also considered reliable biomarkers, in accordance with inflammatory theory (Li et al. 2011).”
BackgroundNeurostimulatory and ablative treatment options in major depressive disorder: a systematic review
Andrade, P., Noblesse, L. H. M., Temel, Y., Ackermans, L., Lim, L. W., Steinbusch, H. W. M., & Visser-Vandewalle, V. (2010) · Acta Neurochirurgica · doi:10.1007/s00701-009-0589-6 · Cited by 53 · cited 1×
“2011), electroconvulsive therapy (Andrade et al. 2010), and other 28 F.”
BackgroundPractical guide for prescribing MAOIs: debunking myths and removing barriers
Grady, M. M., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s109285291200003x · Cited by 51 · cited 1×
“Although recently questioned, it is classically believed that the main side effect of MAOI is the high risk of hypertensive crisis triggered by its combined ingestion with foods containing tyramine, a sympathomimetic amine, which is metabolized by MAO (Grady and Stahl 2012).”
BackgroundPlasma cortisol secretion and REM period latency in adult endogenous depression
(1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.6.750 · Cited by 46 · cited 1×
“system, which exerts a role in both physiologic systems (Asnis et al. 1983).”
BackgroundREM latency concordance in depressed family members
Giles, D. E., Roffwarg, H. P., & Rush, A. J. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90090-4 · Cited by 45 · cited 2×
“associated with depression may be a familiar trait (Giles et al. 1987).”
BackgroundResultDevilbiss, D. M., Jenison, R. L., & Berridge, C. W. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002681 · Cited by 39 · cited 1×
“These results are consistent with clinical symptoms, such as rumination, in which MDD patients are impulsively focused on the past and/or future negative consequences, rather than reflecting on the present moment (Devilbiss et al. 2012).”
ResultIncreased Waking Salivary Cortisol Levels in Young People at Familial Risk of Depression
Mannie, Z. N. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.4.617 · Cited by 37
Tadić, A., Wagner, S., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., & Lieb, K. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-16 · Cited by 33
Dziurkowska, E., Wesołowski, M., & Dziurkowski, M. (2013) · Archives of Women s Mental Health · doi:10.1007/s00737-013-0329-z · Cited by 28 · cited 1×
“Saliva has also been used with success for the measurement of steroid hormones, such as cortisol (Dziurkowska et al. 2013).”
MethodOsório, F. D. L., de Macedo, L. R. H., Sousa, J. P., Pinto, J. P., Quevedo, J., Crippa, J. A. S., & Hallak, J. E. C. (2011) · Cited by 28
Self-citationRelationship between REM sleep latency and nocturnal cortisol concentrations in depressed patients
POLAND, R. E., McCRACKEN, J. T., LUTCHMANSINGH, P., & TONDO, L. (1992) · Journal of Sleep Research · doi:10.1111/j.1365-2869.1992.tb00010.x · Cited by 27 · cited 1×
“and HPA may be interconnected (Poland et al. 1992).”
Altered states and the study of consciousness: The case of Ayahuasca
Shanon, B. (2003) · The Journal of mind and behavior · Cited by 26
Platelet serotonergic markers in posttraumatic stress disorder
Pivac, N., Mück‐Šeler, D., Šagud, M., & Jakovljević, M. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00261-0 · Cited by 22 · cited 1×
“Curiously, plasmatic factors which target the serotoninergic system are not considered good biomarkers for chronic depression (Pivac et al. 2002).”
BackgroundAntidepressants: Current Strategies and Future Opportunities
Gahtori, A., Singh, A., Gahtori, P., Ghosh, S. K., & Ahmad, M. Z. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210794519110 · Cited by 15 · cited 2×
“Thus, enormous effort has been devoted to the search for alternative pharmacological treatments that could improve treatment efficiency and accelerate the onset of therapeutic effects (Uppal et al. 2010).”
BackgroundThe Effect of Globopentaosylceramide on a Depression Model, Mouse Forced Swimming
Masuda, Y., & Sugiyama, T. (2000) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.191.47 · Cited by 14 · cited 1×
“In another study, mice subjected to the forced swimming test, a common paradigm used to study depression in rodents, exhibited decreased immobility time 6 h after receiving DOI, an effect that is considered predictive of antidepressant response (Masuda and Sugiyama 2000).”
BackgroundPrado, D. A., Pinto, J. P., Crippa, J. A. S., Santos, A. C., Ribeiro, S. T. G., Araújo, D., Zuardi, A. W., Chaves, C., & Hallak, J. E. C. (2009) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(09)70469-9 · Cited by 9
Self-citationA58 ANTI-IMMOBILITY EFFECTS OF BETA-CARBOLINES IN THE MOUSE FORCED-SWIM TEST
Farzin, D., & Mansouri, M. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509001-00131 · Cited by 1
Research works printed but not linked: 1
- Fontes, F. P., Ribeiro, S. T. G., Pinto, J. P., Hallak, J. E. C., Crippa, J. A. S., & De Araujo, D. B. (2012). Default Mode Network changes induced by ayahuasca. New Orleans, LA: Paper presented at the Society for Neuroscience Annual Meeting.
Cited by
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
“A growing body of evidence gives support to the observed rapid antidepressant effects of ayahuasca (Palhano-Fontes et al. , 2014).”
ResultSelf-citationOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationdos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Self-citationAyahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
“Anecdotal data also suggest an antidepressant effect for ayahuasca (Palhano-Fontes et al, 2014; Schmid, 2014).”
BackgroundClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“Interest in ayahuasca for the treatment of major depressive disorder (MDD) has also been forthcoming, and stems largely from its influence on serotonergic neurotransmission, where both DMT and &-carboline alkaloids have demonstrated activity (de Lima et al., 2011; Palhano-Fontes et al., 2014).”
Background
Metadata
- Authors
- Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B.
- Affiliations
- Universidade Federal do Rio Grande do Norte (BR)
- Universidade de São Paulo (BR)
- Venue
- The Therapeutic Use of Ayahuasca
- Publisher
- Springer Berlin Heidelberg
- Published
- 2014
- Pages
- 23-39
- OpenAlex
- W55169691
- Semantic Scholar
- 9ec03cce8cb0292990e6590e7d61c722f2d84731
- Cited by
- 36
- References
- 86
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 1
- FWCI
- 20.52
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Springer eBooks (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- ayahuasca, major depressive disorder, depression treatment, N,N-dimethyltryptamine, 5-HT2A receptor, serotonergic neurotransmission, monoamine oxidase inhibitors, antidepressant alternatives, selective serotonin reuptake inhibitors, ketamine, digital object identifiers, β-carbolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.